Peace of Mind for Biomolecule Analysis
Dec 05 2018 Read 841 Times
Shimadzu’s new ‘Nexera Bio’ solution, a biocompatible Ultra-High Performance Liquid Chromatography (UHPLC) system offers the same superior reliability, robustness and expandability as other Nexera series UHPLC systems. It is particularly well suited for analysing protein-based pharmaceuticals, antibody drugs and other substances developed or manufactured using biotechnologies, such as genetic engineering, cell fusion or cell culturing.
The Nexera Bio is compatible with mobile phase solvents containing high concentrations of salts or acids, typically used in the analysis of antibody drugs and membrane proteins, and has also been designed to inhibit peak tailing caused by adsorption to tubing. Such tailing can especially be a problem when analysing phosphorylated peptides, which have a high affinity for metals. Consequently, the Nexera Bio helps ensure that high-quality data is acquired and analysed.
The Nexera Bio is equipped with new and advanced product features such as:
- Maximum corrosion resistance
High salt conditions in the mobile phase can result in corrosion of stainless steel parts in standard UHPLC systems. In the Nexera Bio system, crucial metal-free components define the wetted surfaces while maintaining a high-efficiency flow path (66 MPa). The system is unaffected by high salt content (KH2PO4 in H3PO4) or ion pairing agents (NH4PF6).
- Low surface activity, minimised sample loss
Protein assays can be problematic for traditional HPLC systems, as some proteins can adsorb onto the stainless steel surfaces. Nexera Bio consists of stainless steel casing reinforced PEEK tubing (poly ether ether ketone), a high-performance engineered polymer with mechanical and chemical resistance properties. It ensures a system pressure tolerance of 66 MPa while maintaining an inert flow path. The ceramic injection needle offers metal-free injections and minimised carryover. By dramatically reducing adsorption to metal surfaces in sample flow lines, the Nexera Bio system achieves much higher sensitivity and better reproducibility than the general-purpose UHPLC system.
- Consumables ideal for analysing biopharmaceuticals
The accelerated pace of development of biopharmaceuticals and drugs based on mid-sized molecules, such as peptide drugs and antisense oligonucleotides, has spurred a need for more accurate analytical and evaluation technology applicable for use in supplying and developing higher quality pharmaceuticals. Shim-pack Bio Diol and IEX columns offer performance that can help increase accuracy in analysing and evaluating biopharmaceuticals and drugs based on mid-sized molecules. Available with four different pore sizes, Shim-pack Bio Diol columns are analytical columns suitable for size exclusion chromatography and intended for bioanalysis. They are ideal for analysing aggregates or separating fragments in antibody drugs, separating nucleic acids or sugar chains, and measuring molecular weight. The Shim-pack Bio IEX is an ion-exchange column suitable for separation of proteins and nucleic acids. Shim-pack Bio IEX columns are available either as non-porous or porous type intended for laboratory-scale purification of small quantities.
More information online: www.shimadzu.eu/nexera-bio.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - VMXm takes its First Users 'wher...
View all digital editions
Apr 23 2019 Moscow, Russia
Apr 30 2019 Chicago, IL, USA
Apr 30 2019 Ricoh Arena, Coventry, UK
May 05 2019 St. Louis, MO, USA
May 13 2019 Fort Worth, Tx, USA